{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:46Z","timestamp":1792122226715,"version":"4.4.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"1.3.5 Project of High Altitude Medicine","award":["No. GYYX24003"],"award-info":[{"award-number":["No. GYYX24003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82370192"],"award-info":[{"award-number":["No. 82370192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20680"],"award-info":[{"award-number":["U24A20680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82500270"],"award-info":[{"award-number":["No. 82500270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"West China Hospital, Sichuan University, the Natural Science Foundation of Sichuan Province of China","award":["No. 2025ZNSFSC1692"],"award-info":[{"award-number":["No. 2025ZNSFSC1692"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-026-01199-z","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:22:29Z","timestamp":1770711749000},"page":"167-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma"],"prefix":"10.1007","volume":"21","author":[{"given":"Xinai","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-1014","authenticated-orcid":false,"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2847","authenticated-orcid":false,"given":"Zhengyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04033","volume":"14","author":"J Geng","year":"2024","unstructured":"Geng J, Zhao J, Fan R, et al. Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019. J Glob Health. 2024;14:04033. https:\/\/doi.org\/10.7189\/jogh.14.04033.","journal-title":"J Glob Health"},{"issue":"1","key":"1199_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7.","journal-title":"Nat Rev Dis Primers"},{"key":"1199_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217440","volume":"611","author":"X Dou","year":"2025","unstructured":"Dou X, Duan G, Zhong Y, et al. The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050. Cancer Lett. 2025;611:217440. https:\/\/doi.org\/10.1016\/j.canlet.2025.217440.","journal-title":"Cancer Lett"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.08.003","volume":"21-22","author":"S Blatter","year":"2015","unstructured":"Blatter S, Rottenberg S. Minimal residual disease in cancer therapy \u2013 small things make all the difference. Drug Resist Updat. 2015;21\u201322:1\u201310. https:\/\/doi.org\/10.1016\/j.drup.2015.08.003.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"1199_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche L, Schinke C, Maura F, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022;13(1):4517. https:\/\/doi.org\/10.1038\/s41467-022-32145-y.","journal-title":"Nat Commun"},{"issue":"23","key":"1199_CR6","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399. https:\/\/doi.org\/10.1182\/bloodadvances.2020002827.","journal-title":"Blood Adv"},{"issue":"23","key":"1199_CR7","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456\u201364. https:\/\/doi.org\/10.1182\/blood-2018-06-858613.","journal-title":"Blood"},{"issue":"6","key":"1199_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo M, San-Miguel J, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835\u201344. https:\/\/doi.org\/10.1182\/blood.2021011101.","journal-title":"Blood"},{"issue":"6","key":"1199_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00498-0","volume":"11","author":"S Oliva","year":"2021","unstructured":"Oliva S, Bruinink DHO, Rihova L, et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial. Blood Cancer J. 2021;11(6):106. https:\/\/doi.org\/10.1038\/s41408-021-00498-0.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1199_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144(4):359\u201367. https:\/\/doi.org\/10.1182\/blood.2024024371.","journal-title":"Blood"},{"issue":"11","key":"1199_CR11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1200\/jco-24-02020","volume":"43","author":"Q Shi","year":"2025","unstructured":"Shi Q, Paiva B, Pederson LD, et al. Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials. J Clin Oncol. 2025;43(11):1289\u2013301. https:\/\/doi.org\/10.1200\/jco-24-02020.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1199_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","volume":"22","author":"B Paiva","year":"2025","unstructured":"Paiva B, Shi Q, Puig N, et al. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nat Rev Clin Oncol. 2025;22(6):424\u201338. https:\/\/doi.org\/10.1038\/s41571-025-01017-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"1199_CR13","unstructured":"FDA Oncologic Drugs Advisory Committee. i2TEAMM presentation to support MRD as accelerated approval endpoint. 2024. https:\/\/www.fda.gov\/media\/177738\/download. Accessed 28 July 2025."},{"issue":"8","key":"1199_CR14","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1199_CR15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3324\/haematol.2023.284662","volume":"109","author":"R Szalat","year":"2024","unstructured":"Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024;109(7):2049\u201359. https:\/\/doi.org\/10.3324\/haematol.2023.284662.","journal-title":"Haematologica"},{"issue":"1","key":"1199_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01102-x","volume":"14","author":"J Martinez-Lopez","year":"2024","unstructured":"Martinez-Lopez J, Lopez-Mu\u00f1oz N, Chari A, et al. Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood Cancer J. 2024;14(1):131. https:\/\/doi.org\/10.1038\/s41408-024-01102-x.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1199_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09184-1","volume":"22","author":"A Schmitz","year":"2022","unstructured":"Schmitz A, Br\u00f8ndum RF, Johnsen HE, et al. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission\u2014results from the NMSG flow-MRD substudy within the EMN02\/HO95 MM trial. BMC Cancer. 2022;22(1):147. https:\/\/doi.org\/10.1186\/s12885-022-09184-1.","journal-title":"BMC Cancer"},{"issue":"14","key":"1199_CR18","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","volume":"4","author":"J Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295\u2013301. https:\/\/doi.org\/10.1182\/bloodadvances.2020002037.","journal-title":"Blood Adv"},{"issue":"6","key":"1199_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Dimopoulos MA, et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141(6):579\u201391. https:\/\/doi.org\/10.1182\/blood.2022016782.","journal-title":"Blood"},{"issue":"4","key":"1199_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139(4):492\u2013501. https:\/\/doi.org\/10.1182\/blood.2020010439.","journal-title":"Blood"},{"issue":"25","key":"1199_CR21","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/jco.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889\u2013900. https:\/\/doi.org\/10.1200\/jco.21.02228.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1199_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/jco.20.01814","volume":"39","author":"H Avet-Loiseau","year":"2021","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):1139\u201349. https:\/\/doi.org\/10.1200\/jco.20.01814.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1199_CR23","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/s2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8(6):e422\u201332. https:\/\/doi.org\/10.1016\/s2352-3026(21)00130-7.","journal-title":"Lancet Haematol."},{"issue":"10","key":"1199_CR24","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1182\/bloodadvances.2020001508","volume":"4","author":"R Alonso","year":"2020","unstructured":"Alonso R, Cedena MT, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020;4(10):2163\u201371. https:\/\/doi.org\/10.1182\/bloodadvances.2020001508.","journal-title":"Blood Adv"},{"issue":"10","key":"1199_CR25","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1080\/10428194.2024.2358857","volume":"65","author":"QQ Cui","year":"2024","unstructured":"Cui QQ, Li ZH, Ma YP. MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma. Leuk Lymphoma. 2024;65(10):1430\u20137. https:\/\/doi.org\/10.1080\/10428194.2024.2358857.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1199_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.20892\/j.issn.2095-3941.2022.0612","volume":"20","author":"H Fan","year":"2023","unstructured":"Fan H, Wang W, Zhang Y, et al. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study. Cancer Biol Med. 2023;20(1):77\u201387. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0612.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"1199_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00794-x","volume":"13","author":"R Fonseca","year":"2023","unstructured":"Fonseca R, Arribas M, Wiedmeier-Nutor JE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13(1):32. https:\/\/doi.org\/10.1038\/s41408-023-00794-x.","journal-title":"Blood Cancer J"},{"issue":"3","key":"1199_CR28","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan M, Kendrick S, Szabo A, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808\u201317. https:\/\/doi.org\/10.1182\/bloodadvances.2021005822.","journal-title":"Blood Adv"},{"issue":"1","key":"1199_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00891-8","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Li J, Zhang R, Li J, Chen L, Jin Y. Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma. Discov Oncol. 2024;15(1):38. https:\/\/doi.org\/10.1007\/s12672-024-00891-8.","journal-title":"Discov Oncol"},{"issue":"6","key":"1199_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2024.100252","volume":"24","author":"W Xu","year":"2024","unstructured":"Xu W, Liang X, Liu S, et al. Dynamics of minimal residual disease and its clinical implications in multiple myeloma: a retrospective real-life analysis. Clin Med (Lond). 2024;24(6):100252. https:\/\/doi.org\/10.1016\/j.clinme.2024.100252.","journal-title":"Clin Med (Lond)"},{"issue":"11","key":"1199_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/jco-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol. 2025;43(11):1279\u201388. https:\/\/doi.org\/10.1200\/jco-24-02266.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1199_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1182\/blood.2024027674","volume":"146","author":"S Giri","year":"2025","unstructured":"Giri S, Dhakal B, Callander NS, et al. Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma. Blood. 2025;146(6):707\u201316. https:\/\/doi.org\/10.1182\/blood.2024027674.","journal-title":"Blood"},{"issue":"30","key":"1199_CR33","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3760\/cma.j.cn112137-20211226-02892","volume":"102","author":"GZ Yang","year":"2022","unstructured":"Yang GZ, Wang GR, Wang HJ, et al. The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era [in Chinese]. Zhonghua Yi Xue Za Zhi. 2022;102(30):2345\u201350. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20211226-02892.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"7","key":"1199_CR34","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3760\/cma.j.issn.0253-2727.2019.07.009","volume":"40","author":"PY Yang","year":"2019","unstructured":"Yang PY, Liu MM, Fan HQ, et al. The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(7):584\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2019.07.009.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"2","key":"1199_CR35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41375-019-0590-x","volume":"34","author":"G An","year":"2020","unstructured":"An G, Yan Y, Xu Y, et al. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020;34(2):578\u201388. https:\/\/doi.org\/10.1038\/s41375-019-0590-x.","journal-title":"Leukemia"},{"issue":"1","key":"1199_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2024014097","volume":"9","author":"LY Chen","year":"2025","unstructured":"Chen LY, Thibaud S, Bodnar S, et al. MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma. Blood Adv. 2025;9(1):176\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2024014097.","journal-title":"Blood Adv"},{"key":"1199_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2024-203818","volume":"144","author":"RZ Orlowski","year":"2024","unstructured":"Orlowski RZ, Dimopoulos MA, Leleu X, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma (NDMM): analyses of minimal residual disease (MRD) negativity dynamics in the phase 3 IMROZ study [66th ASH Annual Meeting abstract 654 + poster]. Blood. 2024;144:770\u20132. https:\/\/doi.org\/10.1182\/blood-2024-203818.","journal-title":"Blood"},{"issue":"17","key":"1199_CR38","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2400712.","journal-title":"N Engl J Med"},{"issue":"1","key":"1199_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06543-x","volume":"23","author":"N An","year":"2025","unstructured":"An N, Li J, Luo P, et al. Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed\/refractory multiple myeloma. J Transl Med. 2025;23(1):552. https:\/\/doi.org\/10.1186\/s12967-025-06543-x.","journal-title":"J Transl Med"},{"issue":"5","key":"1199_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2643-3230.Bcd-23-0044","volume":"4","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Rytlewski J, et al. Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood Cancer Discov. 2023;4(5):365\u201373. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-23-0044.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"1199_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ajh.27526","volume":"100","author":"A Zabaleta","year":"2025","unstructured":"Zabaleta A, Puig N, Cedena MT, et al. Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. Am J Hematol. 2025;100(1):93\u2013102. https:\/\/doi.org\/10.1002\/ajh.27526.","journal-title":"Am J Hematol"},{"issue":"5","key":"1199_CR42","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403407.","journal-title":"N Engl J Med"},{"issue":"5","key":"1199_CR43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2405090.","journal-title":"N Engl J Med"},{"issue":"9","key":"1199_CR44","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","volume":"8","author":"BA Derman","year":"2022","unstructured":"Derman BA, Kansagra A, Zonder J, et al. Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study. JAMA Oncol. 2022;8(9):1278\u201386. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2424.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1199_CR45","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1002\/ajh.26150","volume":"96","author":"N Korde","year":"2021","unstructured":"Korde N, Mastey D, Tavitian E, et al. Tailored treatment to MRD response: a phase I\/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56\u2009mg\/m2) in combination with lenalidomide and dexamethasone. Am J Hematol. 2021;96(6):e193\u20136. https:\/\/doi.org\/10.1002\/ajh.26150.","journal-title":"Am J Hematol"},{"issue":"11","key":"1199_CR46","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/s2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810\u201321. https:\/\/doi.org\/10.1016\/s2352-3026(22)00263-0.","journal-title":"Lancet Haematol."},{"issue":"5","key":"1199_CR47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa2505133","volume":"393","author":"A Perrot","year":"2025","unstructured":"Perrot A, Lambert J, Hulin C, et al. Measurable residual disease-guided therapy in newly diagnosed myeloma. N Engl J Med. 2025;393(5):425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2505133.","journal-title":"N Engl J Med"},{"issue":"1","key":"1199_CR48","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1182\/blood-2024-202079","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Kazandjian D. Advance multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients [66th ASH Annual Meeting abstract 654]. Blood. 2024;144(1):7035\u20136. https:\/\/doi.org\/10.1182\/blood-2024-202079.","journal-title":"Blood"},{"key":"1199_CR49","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1182\/blood-2024-200210","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Silbermann R, Schmidt TM, et al. MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM)-Master-2 trial [66th ASH annual meeting abstract 654]. Blood. 2024;144:7061\u20133. https:\/\/doi.org\/10.1182\/blood-2024-200210.","journal-title":"Blood"},{"issue":"25","key":"1199_CR50","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/jco.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901\u201312. https:\/\/doi.org\/10.1200\/jco.21.01935.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1199_CR51","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/s2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(11):e890-901. https:\/\/doi.org\/10.1016\/s2352-3026(23)00236-3.","journal-title":"Lancet Haematol."},{"issue":"1","key":"1199_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14(1):170. https:\/\/doi.org\/10.1038\/s41408-024-01156-x.","journal-title":"Blood Cancer J"},{"issue":"18","key":"1199_CR53","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos R, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142(18):1518\u201328. https:\/\/doi.org\/10.1182\/blood.2022019531.","journal-title":"Blood"},{"issue":"20","key":"1199_CR54","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1182\/blood.2024027686","volume":"145","author":"E Terpos","year":"2025","unstructured":"Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 2025;145(20):2353\u201360. https:\/\/doi.org\/10.1182\/blood.2024027686.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1199_CR55","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/S2152-2650(24)01856-1","volume":"24","author":"N Korde","year":"2024","unstructured":"Korde N, Hassoun H, Landau H, et al. Maintenance therapy cessation for three-year sustained MRD negative multiple myeloma patients [IMS abstract OA-15]. Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 2):S10\u20131. https:\/\/doi.org\/10.1016\/S2152-2650(24)01856-1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1199_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01135-w","volume":"14","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Alonso R, Wong SW, et al. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021;14(1):126. https:\/\/doi.org\/10.1186\/s13045-021-01135-w.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"1199_CR57","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):608\u2013700. https:\/\/doi.org\/10.1038\/s41571-025-01041-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1199_CR58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jha2.633","volume":"4","author":"R Urushihara","year":"2023","unstructured":"Urushihara R, Takezako N, Yoroidaka T, et al. Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal\/measurable residual disease in autografts of patients with multiple myeloma. EJHaem. 2023;4(1):184\u201391. https:\/\/doi.org\/10.1002\/jha2.633.","journal-title":"EJHaem"},{"issue":"6","key":"1199_CR59","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.4103\/jcrt.JCRT_1027_19","volume":"17","author":"P Sharma","year":"2021","unstructured":"Sharma P, Singh Sachdeva MU, Varma N, Bose P, Aggarwal R, Malhotra P. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data. J Cancer Res Ther. 2021;17(6):1515\u201320. https:\/\/doi.org\/10.4103\/jcrt.JCRT_1027_19.","journal-title":"J Cancer Res Ther"},{"issue":"10","key":"1199_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00377-0","volume":"10","author":"A Medina","year":"2020","unstructured":"Medina A, Puig N, Flores-Montero J, et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10(10):108. https:\/\/doi.org\/10.1038\/s41408-020-00377-0.","journal-title":"Blood Cancer J"},{"key":"1199_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932852","volume":"12","author":"V Ferla","year":"2022","unstructured":"Ferla V, Antonini E, Perini T, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy. Front Oncol. 2022;12:932852. https:\/\/doi.org\/10.3389\/fonc.2022.932852.","journal-title":"Front Oncol"},{"issue":"1","key":"1199_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00938-w","volume":"15","author":"M Zhou","year":"2024","unstructured":"Zhou M, Chen Y, Gong Y, et al. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. Discov Oncol. 2024;15(1):78. https:\/\/doi.org\/10.1007\/s12672-024-00938-w.","journal-title":"Discov Oncol"},{"issue":"10","key":"1199_CR63","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u2013103. https:\/\/doi.org\/10.1038\/leu.2017.29.","journal-title":"Leukemia"},{"issue":"5","key":"1199_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051605","volume":"15","author":"A Salgado","year":"2023","unstructured":"Salgado A, Magalh\u00e3es RJP, Pontes RM, et al. Lenalidomide maintenance and measurable residual disease in a real-world multiple myeloma transplanted population receiving different treatment strategies guided by access to novel drugs in Brazil. Cancers (Basel). 2023;15(5):1605. https:\/\/doi.org\/10.3390\/cancers15051605.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1199_CR65","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/10408363.2023.2209652","volume":"60","author":"C Wijnands","year":"2023","unstructured":"Wijnands C, Noori S, Donk N, VanDuijn MM, Jacobs JFM. Advances in minimal residual disease monitoring in multiple myeloma. Crit Rev Clin Lab Sci. 2023;60(7):518\u201334. https:\/\/doi.org\/10.1080\/10408363.2023.2209652.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"1199_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00418-2","volume":"11","author":"BA Derman","year":"2021","unstructured":"Derman BA, Stefka AT, Jiang K, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021;11(2):19. https:\/\/doi.org\/10.1038\/s41408-021-00418-2.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1199_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010135","volume":"17","author":"C Wijnands","year":"2025","unstructured":"Wijnands C, Karel PGA, Gloerich J, et al. Monitoring M-protein, therapeutic antibodies, and polyclonal antibodies in a multiparametric mass spectrometry assay provides insight into therapy response kinetics in patients with multiple myeloma. Pharmaceutics. 2025;17(1):135. https:\/\/doi.org\/10.3390\/pharmaceutics17010135.","journal-title":"Pharmaceutics"},{"issue":"9","key":"1199_CR68","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1016\/j.clml.2025.04.017","volume":"25","author":"MJ Slade","year":"2025","unstructured":"Slade MJ, Fortier J, Khaled A, et al. Blood-based measurable residual disease by clonotypic mass spectrometry is prognostic in patients with multiple myeloma undergoing autologous hematopoietic cell transplant. Clin Lymphoma Myeloma Leuk. 2025;25(9):e628-37.e4. https:\/\/doi.org\/10.1016\/j.clml.2025.04.017.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"1199_CR69","doi-asserted-by":"publisher","first-page":"E230","DOI":"10.1002\/ajh.26995","volume":"98","author":"A Belotti","year":"2023","unstructured":"Belotti A, Ribolla R, Crippa C, et al. Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma. Am J Hematol. 2023;98(9):E230\u20132. https:\/\/doi.org\/10.1002\/ajh.26995.","journal-title":"Am J Hematol"},{"issue":"24","key":"1199_CR70","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/jco-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43(24):2739\u201351. https:\/\/doi.org\/10.1200\/jco-24-01893.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1199_CR71","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.18211","volume":"198","author":"H Cho","year":"2022","unstructured":"Cho H, Shin S, Chung H, et al. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma. Br J Haematol. 2022;198(3):503\u201314. https:\/\/doi.org\/10.1111\/bjh.18211.","journal-title":"Br J Haematol"},{"issue":"1","key":"1199_CR72","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-024-01075-x","volume":"14","author":"M D'Agostino","year":"2024","unstructured":"D\u2019Agostino M, Rota-Scalabrini D, Belotti A, et al. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. Blood Cancer J. 2024;14(1):94. https:\/\/doi.org\/10.1038\/s41408-024-01075-x.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1199_CR73","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00277-019-03609-x","volume":"98","author":"H Li","year":"2019","unstructured":"Li H, Li F, Zhou X, et al. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis. Ann Hematol. 2019;98(5):1185\u201395. https:\/\/doi.org\/10.1007\/s00277-019-03609-x.","journal-title":"Ann Hematol"},{"issue":"20","key":"1199_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70270","volume":"13","author":"D Liang","year":"2024","unstructured":"Liang D, Li X, Bai S, et al. Clinical outcome of induction treatment in the era of novel agents and the impact of the number of high-risk cytogenetic abnormalities (HRA) on prognosis of patients with newly diagnosed multiple myeloma (NDMM): insights from a multicenter study. Cancer Med. 2024;13(20):e70270. https:\/\/doi.org\/10.1002\/cam4.70270.","journal-title":"Cancer Med"},{"issue":"8","key":"1199_CR75","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/jco.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784\u201392. https:\/\/doi.org\/10.1200\/jco.19.01231.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1199_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12077-0","volume":"24","author":"Y Tao","year":"2024","unstructured":"Tao Y, Jin S, Yang D, et al. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma. BMC Cancer. 2024;24(1):406. https:\/\/doi.org\/10.1186\/s12885-024-12077-0.","journal-title":"BMC Cancer"},{"issue":"2","key":"1199_CR77","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.26774","volume":"98","author":"P Yang","year":"2023","unstructured":"Yang P, Chen H, Liang X, et al. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma. Am J Hematol. 2023;98(2):251\u201363. https:\/\/doi.org\/10.1002\/ajh.26774.","journal-title":"Am J Hematol"},{"issue":"5","key":"1199_CR78","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.31854","volume":"125","author":"M Gambella","year":"2019","unstructured":"Gambella M, Omed\u00e9 P, Spada S, et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer. 2019;125(5):750\u201360. https:\/\/doi.org\/10.1002\/cncr.31854.","journal-title":"Cancer"},{"issue":"1","key":"1199_CR79","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","volume":"137","author":"I Goicoechea","year":"2021","unstructured":"Goicoechea I, Puig N, Cedena MT, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021;137(1):49\u201360. https:\/\/doi.org\/10.1182\/blood.2020006731.","journal-title":"Blood"},{"issue":"3","key":"1199_CR80","doi-asserted-by":"publisher","first-page":"E61","DOI":"10.1002\/ajh.26810","volume":"98","author":"P Yang","year":"2023","unstructured":"Yang P, Xu W, Liang X, et al. Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. Am J Hematol. 2023;98(3):E61\u20134. https:\/\/doi.org\/10.1002\/ajh.26810.","journal-title":"Am J Hematol"},{"issue":"7","key":"1199_CR81","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2023022083","volume":"143","author":"C Guerrero","year":"2024","unstructured":"Guerrero C, Puig N, Cedena MT, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024;143(7):597\u2013603. https:\/\/doi.org\/10.1182\/blood.2023022083.","journal-title":"Blood"},{"issue":"9","key":"1199_CR82","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1158\/2767-9764.Crc-23-0185","volume":"3","author":"J Liu","year":"2023","unstructured":"Liu J, Yan W, Fan H, et al. Clinical benefit of autologous stem cell transplantation for patients with multiple myeloma achieving undetectable minimal residual disease after induction treatment. Cancer Res Commun. 2023;3(9):1770\u201380. https:\/\/doi.org\/10.1158\/2767-9764.Crc-23-0185.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"1199_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood.2024026230","volume":"146","author":"A Perrot","year":"2025","unstructured":"Perrot A, Touzeau C, Lambert J, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. Blood. 2025;146(1):52\u201361. https:\/\/doi.org\/10.1182\/blood.2024026230.","journal-title":"Blood"},{"issue":"12","key":"1199_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70031","volume":"8","author":"V Gonz\u00e1lez-Calle","year":"2024","unstructured":"Gonz\u00e1lez-Calle V, Rodriguez-Otero P, Calasanz MJ, et al. High\u2010risk cytogenetic abnormalities in multiple myeloma: PETHEMA\u2010GEM experience. HemaSphere. 2024;8(12):e70031. https:\/\/doi.org\/10.1002\/hem3.70031.","journal-title":"HemaSphere"},{"issue":"1","key":"1199_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97125-w","volume":"15","author":"J Mao","year":"2025","unstructured":"Mao J, Xue L, Wang H, et al. Cytogenetic risk stratification combined with minimal residual disease status influences the therapeutic outcome and prognosis of multiple myelomas. Sci Rep. 2025;15(1):12545. https:\/\/doi.org\/10.1038\/s41598-025-97125-w.","journal-title":"Sci Rep"},{"issue":"5","key":"1199_CR86","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/j.clml.2020.01.001","volume":"20","author":"C Kunacheewa","year":"2020","unstructured":"Kunacheewa C, Lee HC, Patel K, et al. Minimal residual disease negativity does not overcome poor prognosis in high-risk multiple myeloma: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2020;20(5):e221\u201338. https:\/\/doi.org\/10.1016\/j.clml.2020.01.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"1199_CR87","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cncr.34641","volume":"129","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xu J, Xu B, et al. The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: the faster, the worse. Cancer. 2023;129(7):1005\u201316. https:\/\/doi.org\/10.1002\/cncr.34641.","journal-title":"Cancer"},{"key":"1199_CR88","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000443","author":"F Gay","year":"2023","unstructured":"Gay F, Bertuglia G, Mina R. A rational approach to functional high-risk myeloma. Hematol Am Soc Hematol Educ Progr. 2023. https:\/\/doi.org\/10.1182\/hematology.2023000443.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"1199_CR89","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1182\/blood-2023-189022","volume":"142","author":"FB Askeland","year":"2023","unstructured":"Askeland FB, Rasmussen A-M, Lysen A, et al. Will survival improve by treating multiple myeloma patients at MRD relapse? The REMNANT study [65th ASH annual meeting abstract 653]. Blood. 2023;142:4755. https:\/\/doi.org\/10.1182\/blood-2023-189022.","journal-title":"Blood"},{"key":"1199_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00699","volume":"9","author":"A Romano","year":"2019","unstructured":"Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C. Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives. Front Oncol. 2019;9:699. https:\/\/doi.org\/10.3389\/fonc.2019.00699.","journal-title":"Front Oncol"},{"issue":"14","key":"1199_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","volume":"15","author":"A Medina-Herrera","year":"2023","unstructured":"Medina-Herrera A, Sarasquete ME, Jimenez C, Puig N, Garcia-Sanz R. Minimal residual disease in multiple myeloma: past, present, and future. Cancers (Basel). 2023;15(14):3687. https:\/\/doi.org\/10.3390\/cancers15143687.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1199_CR92","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/j.clml.2021.07.032","volume":"22","author":"A O\u2019Brien","year":"2022","unstructured":"O\u2019Brien A, O\u2019Halloran F, Mykytiv V. Minimal residual disease in multiple myeloma: potential for blood-based methods to monitor disease. Clin Lymphoma Myeloma Leuk. 2022;22(1):e34-40. https:\/\/doi.org\/10.1016\/j.clml.2021.07.032.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"1199_CR93","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337\u201345. https:\/\/doi.org\/10.1182\/blood.2019000241.","journal-title":"Blood"},{"issue":"2","key":"1199_CR94","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12185-025-03966-6","volume":"122","author":"S Sato","year":"2025","unstructured":"Sato S, Sawazaki E, Tsunoda S, Kamata W, Togano T, Tamai Y. Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma. Int J Hematol. 2025;122(2):217\u201333. https:\/\/doi.org\/10.1007\/s12185-025-03966-6.","journal-title":"Int J Hematol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01199-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:58Z","timestamp":1774630678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01199-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01199-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xinai Gan, Linfeng Li, Li Zhang, Yuhuan Zheng, Ting Niu, and Zhengyu Yu declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the preparation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Xinai Gan and Linfeng Li conceived and designed research, obtained original research data, and analyzed and interpreted the results. Xinai Gan and Zhengyu Yu analyzed the data and wrote the manuscript. Li Zhang, Yuhuan Zheng, Ting Niu, and Zhengyu Yu revised the manuscript and interpreted the results. All authors discussed and provided critical comments and approved the final version for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}